businessneutral
Pfizer's Q4 2024: Beating Expectations, Facing Challenges
New York, USATuesday, February 4, 2025
Pfizer's long-term prosperity remains a key issue for investors. They are also looking at the company's pipeline of new drugs. One area that'll grab their attention is Pfizer's possible breakthrough in the weight loss drug market. The company is working on a once-daily version of its experimental obesity pill, danuglipron. If successful, this could open up a new revenue stream.
Another point of interest is the ongoing situation with activist investor Starboard Value. At the moment, it looks like Pfizer has dodged a potential proxy battle. This was possible because the deadline for nominating board members for 2024 has passed. Starboard Value, which owns $1 billion in Pfizer stocks, had left open the possibility of shaking things up.
The next few years will be crucial for Pfizer. They need to adjust to the decreasing demand for COVID-19 products and continue to innovate in new markets. The company's ability to weather these changes could greatly impact its future success.
Actions
flag content